RT Book, Section
A1 Faries, Mark B.
A2 Morita, Shane Y.
A2 Balch, Charles M.
A2 Klimberg, V. Suzanne
A2 Pawlik, Timothy M.
A2 Posner, Mitchell C.
A2 Tanabe, Kenneth K.
SR Print(0)
ID 1145755896
T1 Sentinel Lymph Node Biopsy for Melanoma
T2 Textbook of Complex General Surgical Oncology
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071793315
LK hemonc.mhmedical.com/content.aspx?aid=1145755896
RD 2024/04/18
AB Sentinel  lymph  node  (SLN)  biopsy  is  now  a  standard  component  of  the  treatment  of  many  melanomas,  and  its  use  is  accepted  as  routine.1,2  So  routine,  in  fact,  that  the  revolutionary  nature  of  its  beginning  is  little  remembered.  This  is  appropriate  as  the  technique  and  the  clinical  data  supporting  its  use  are  now  both  broad  and  deep.  However,  even  with  our  familiarity  with  the  procedure,  it  is  important  to  remember  that  the  technique  requires  skill  and  coordination  of  multiple  disciplines  and  that  appropriate  selection  of  candidates  for  SLN  biopsy  is  necessary.  The  impact  of  SLN  biopsy  has  now  spread  from  melanoma  to  breast  cancer,  and  may  become  more  common  in  other  solid  tumors.  The  benefits  it  has  produced  for  melanoma  patients  around  the  world  including  more  accurate  staging  and  less  morbid  treatment  of  regional  lymph  nodes  are  remarkable  and  will  ensure  that  SLN  biopsy  will  continue  to  be  a  vital  component  of  melanoma  treatment  into  the  future.